(4-chlorophenyl)(pyridin-4-yl)methanol | 36938-77-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-chlorophenyl)(pyridin-4-yl)methanol
• 英文别名: (pyridin-4-yl)-(4-chlorophenyl)methanol；(4-Pyridyl)-(4-chlorophenyl)methanol；(4-chlorophenyl)-pyridin-4-ylmethanol
• CAS: 36938-77-9
• 化学式: C₁₂H₁₀ClNO
• 分子量: 219.671
• InChiKey: FPHTYYCDRPINKU-UHFFFAOYSA-N

物化性质

• 熔点：
  135-136 °C
• 沸点：
  388.6±32.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-chlorophenyl)(pyridin-4-yl)methanol 在 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 76.5h， 生成 1-[4-chlorophenyl(pyridin-4-yl)methyl]piperazine
  参考文献：
  名称：

  Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine

  摘要：

  The synthesis of a variety of novel 4-amido, 4-carbamoyl and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin -11-yl)piperazine to explore the SAR of of this series of FPT inhibitors is described. This resulted in the synthesis of the 4- and 3-pyridylacetyl analogues 45a and 50a, respectively, both of which were orally active but were found to be rapidly metabolized in vivo. Identification of the principal metabolites led to the synthesis of a variety of new compounds that would be less readily metabolized, the most interesting of which were the 3- and 4-pyridylacetyl N-oxides 80a and 83a. Novel replacements for the pyridylacetyl moiety were also sought, and this resulted in the discovery of the 4-N-methyl and 4-N-carboxamidopiperidinylacetyl derivatives 135a and 160a, respectively. All of these derivatives exhibited greatly improved pharmacokinetics. The synthesis of the corresponding 3-bromo analogues resulted in the discovery of the 4-pyridylacetyl N-oxides 83b (+/-) and 85b [11S(-)] and the 4-carboxamidopiperidinylacetamido derivative 160b (+/-), all of which exhibited potent FPT inhibition in vitro. All three showed excellent oral bioavailability in vivo in nude mice and cynomolgus monkeys and exhibited excellent antitumor efficacy against a series of tumor cell lines when dosed orally in nude mice.

  DOI：

  10.1021/jm970462w
• 作为产物：
  描述：

  4-(4-氯苯甲酰氯)吡啶 在 immobilized baker's yeast 作用下， 以 正己烷 为溶剂， 反应 336.0h， 以5%的产率得到(4-chlorophenyl)(pyridin-4-yl)methanol
  参考文献：
  名称：

  抑制剂或固定化对面包酵母还原苯甲酰吡啶的影响。

  摘要：

  苯甲酰吡啶衍生物（1a-e）通过酵母的还原立体化学过程可以通过固定化或用烯丙醇或氯乙酸乙酯处理还原体系来进行调节。

  DOI：

  10.1248/cpb.44.853

文献信息

• Azetidine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20010027193A1

  公开（公告）日：2001-10-04

  Compounds of formula: 1 in which R represents a CR 1 R 2 , C═C(R 5 )SO 2 R 6 or C═C(R 7 )SO 2 alk radical, their preparation and the pharmaceutical compositions containing them.

  式1中R代表CR1R2、C═C(R5)SO2R6或C═C(R7)SO2烷基基团，它们的制备以及含有它们的药物组合物。
• Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
  申请人：Aventis Pharma S.A.

  公开号：US06355631B1

  公开（公告）日：2002-03-12

  The present invention relates to pharmaceutical compositions containing, as an active ingredient, at least one compound of formula: in which R1 represents a radical —N(R4)R5, —N(R4)—CO—R5, —N(R4)—SO2R6 or one of its pharmaceutically acceptable salts, to the novel derivatives of formula (I), to their pharmaceutically acceptable salts and to their preparation.

  本发明涉及含有至少一种化合物的药物组合物，其作为活性成分，该化合物的结构式为：其中R1代表基团—N(R4)R5，—N(R4)—CO—R5，—N(R4)—SO2R6或其药学上可接受的盐，以及结构式（I）的新衍生物，其药学上可接受的盐以及它们的制备方法。
• Metal-Free Synthesis of C-4 Substituted Pyridine Derivatives Using Pyridine-boryl Radicals via a Radical Addition/Coupling Mechanism: A Combined Computational and Experimental Study
  作者：Guoqiang Wang、Jia Cao、Liuzhou Gao、Wenxin Chen、Wenhao Huang、Xu Cheng、Shuhua Li

  DOI：10.1021/jacs.7b00823

  日期：2017.3.15

  that the pyridine-boryl radical generated in situ using 4-cyanopyridine and bis(pinacolato)diboron could be used as a bifunctional "reagent", which serves as not only a pyridine precursor but also a boryl radical. With the unique reactivity of such radicals, 4-substituted pyridine derivatives could be synthesized using α,β-unsaturated ketones and 4-cyanopyridine via a novel radical addition/C-C coupling

  密度泛函理论研究表明，使用 4-氰基吡啶和双（频哪醇）二硼原位生成的吡啶-硼基自由基可用作双功能“试剂”，其不仅可用作吡啶前体，还可用作硼基自由基。由于这些自由基的独特反应性，可以使用α,β-不饱和酮和4-氰基吡啶通过新型自由基加成/CC偶联机制合成4-取代吡啶衍生物。进行了几个对照实验，为所提出的机制提供支持性证据。除了烯酮，范围还可以扩展到广泛的硼基自由基受体，包括各种醛和酮、芳基亚胺和炔酮。最后，这种转化应用于复杂药物分子的后期修饰。
• Novel IL-5 inhibiting 6-azauracil derivatives
  申请人：——

  公开号：US20020072603A1

  公开（公告）日：2002-06-13

  The present invention is concerned with the compounds of formula 1 the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, p and q are 0, 1, 2, 3 or 4 and q is also 5; X is O, S, NR 3 or a direct bond; R 1 is hydrogen, hydroxy, halo, optionally substituted amino, optionally substituted C 1-6 alkyl, C 1-6 alkyloxy, C 3-7 cycloalkyl or aryl; R 2 is aryl, Het 1 , C 3-7 cycloalkyl, optionally substituted C 1-6 alkyl; and if X is O, S or NR 3 , then R 2 may also be a carbonyl or thiocarbonyl linked substituent; R 3 is hydrogen or C 1-4 alkyl; R 4 and R 5 independently are optionally substituted C 1-6 alkyl, halo, hydroxy, mercapto, C 1-6 alkyloxy, C 1-6 akylthio, C 1-6 alkylcarbonyloxy, aryl, cyano, nitro, Het 3 , R 6 or NR 7 R 8 ; R 6 is substituted sulfonyl or sulfinyl; R 7 and R 8 are hydrogen, optionally substituted C 1-4 alkyl, aryl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 9 and R 10 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 11 is hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C 1-4 alkyloxy, carboxyl, C 1-4 alkyloxycarbonyl, trihaloC 1-4 alkylsulfonyloxy, R 6 , NR 7 R 8 , C(═O)NR 7 R 8 , aryl, aryloxy, arylcarbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, phthalimide-2-yl, Het 3 and C(═O)Het 3 ; R 12 and R 13 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl and R 6 ; aryl is optionally substituted phenyl; Het 1 , Het 2 and Het 3 are optionally substituted heterocycles; to processes for their preparation and compositions comprising them. It further relates to their use as a medicine.

  本发明涉及公式1的化合物，包括N-氧化物、药学上可接受的加合盐以及其立体化异构体形式，其中p和q为0、1、2、3或4，q也可以为5；X为O、S、NR3或直接键；R1为氢、羟基、卤素、可选择取代的氨基、可选择取代的C1-6烷基、C1-6烷氧基、C3-7环烷基或芳基；R2为芳基、Het1、C3-7环烷基、可选择取代的C1-6烷基；如果X为O、S或NR3，则R2也可以是羰基或硫代羰基连接的取代基；R3为氢或C1-4烷基；R4和R5独立地为可选择取代的C1-6烷基、卤素、羟基、巯基、C1-6烷氧基、C1-6烷硫基、C1-6烷基羰氧基、芳基、氰基、硝基、Het3、R6或NR7R8；R6为取代磺酰基或亚砜基；R7和R8为氢、可选择取代的C1-4烷基、芳基、羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R9和R10各自独立地选自氢、可选择取代的C1-4烷基、苯基、羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R11为羟基、巯基、氰基、硝基、卤素、三卤甲基、C1-4烷氧基、羧基、C1-4烷氧羰基、三卤代C1-4烷基磺酰氧基、R6、NR7R8、C(═O)NR7R8、芳基、芳氧基、芳基羰基、C3-7环烷基、C3-7环烷氧基、邻苯二甲酰亚胺-2-基、Het3和C(═O)Het3；R12和R13各自独立地选自氢、可选择取代的C1-4烷基、苯基、羰基或硫代羰基连接的取代基、C3-7环烷基和R6；芳基为可选择取代的苯基；Het1、Het2和Het3为可选择取代的杂环；以及其制备方法和包含它们的组合物。进一步涉及它们作为药物的用途。
• Benzylic C–H heteroarylation of <i>N</i>-(benzyloxy)phthalimides with cyanopyridines enabled by photoredox 1,2-hydrogen atom transfer
  作者：Long-Jin Zhong、Hong-Yu Wang、Xuan-Hui Ouyang、Jin-Heng Li、De-Lie An

  DOI：10.1039/d0cc03619f

  日期：——

  A visible light initiated α-C(sp3)–H arylation of N-(benzyloxy)phthalimides with cyanopyridines for the construction of highly valuable pyridinyl-containing diarylmethanols, including bioactive motif-based analogues, is reported. This method enables arylation of the C(sp3)–H bonds adjacent to an oxygen atom through alkoxy radical formation by O–N bond cleavage, 1,2-hydrogen atom transfer (HAT), arylation

  据报道，可见光引发了N-（苄氧基）邻苯二甲酰亚胺与氰基吡啶的α-C（sp 3）-H芳基化反应，用于构建高度有价值的含吡啶基二芳基甲醇，包括基于生物活性基序的类似物。这种方法通过O-N键裂解，1,2-氢原子转移（HAT），芳基化和C-CN键裂解级联，通过与烷氧基基团相邻的氧原子进行C（sp 3）-H键芳基化，并提供了一种利用1,2-HAT模式并入官能团以构建官能化醇的方法。